Last reviewed · How we verify
NCT05179447: PROBEAT
PROfiling Based Endometrial Cancer Adjuvant Therapy
NA trial testing Vaginal brachytherapy in Endometrial Cancer Stage I in 590 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Women's Hospital School Of Medicine Zhejiang University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 590 |
| Start date | 24 January 2022 |
| Primary completion | 31 December 2026 |
| Estimated completion | 1 January 2027 |
| Sites | 10 locations across China |
Drugs / interventions tested
- Vaginal brachytherapy
- External beam radiotherapy
- Observation
- Chemoradiation therapy
Conditions studied
- Endometrial Cancer Stage I — all drugs for Endometrial Cancer Stage I →
- Endometrial Cancer Stage II — all drugs for Endometrial Cancer Stage II →
Sponsor
Women's Hospital School Of Medicine Zhejiang University
Who can join
Adults 18 to 75, female only, with Endometrial Cancer Stage I or Endometrial Cancer Stage II. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).
Li Y, Zhu C, Xie H, Chen Y, et al · · 2023 · cited 6× · PMID 36659832 · DOI 10.3802/jgo.2023.34.e37 -
Unsolved Issues in the Integrated Histo-Molecular Classification of Endometrial Carcinoma and Therapeutic Implications.
Kuhn E, Gambini D, Runza L, Ferrero S, et al · · 2024 · cited 4× · PMID 39001520 · DOI 10.3390/cancers16132458 -
The impact of integrated genomic analysis on molecular classifications and prognostic risk stratification in endometrial cancer: a Chinese experience.
Zheng Q, Shao D, Shu J, Zhang Q, et al · · 2025 · PMID 39980551 · DOI 10.3389/fonc.2025.1541562
Verify or expand the search:
- PubMed search for NCT05179447
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vaginal brachytherapy
Trials testing the same drug.
- NCT05857631 — Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study · NA · recruiting
- NCT05640999 — Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER · Phase 2 · recruiting
- NCT05524389 — Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide A · Phase 3 · not yet recruiting
- NCT05255653 — Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features · Phase 2, PHASE3 · recruiting
- NCT03469674 — PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer · Phase 3 · active not recruiting
Other recruiting trials for Endometrial Cancer Stage I
Currently open trials in the same condition.
- NCT07040657 — Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometria · NA · recruiting
- NCT06278857 — SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) · Phase 2 · recruiting
- NCT06417736 — Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women · NA · recruiting
- NCT04839614 — Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial · NA · recruiting
- NCT04291612 — Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease · recruiting
Other Women's Hospital School Of Medicine Zhejiang University trials
Trials by the same sponsor.
- NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
- NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
- NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
- NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
- NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05179447 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
- Last refreshed: 1 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05179447.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing